Vertex Pharmaceuticals announced major progress in its kidney disease pipeline, including FDA Breakthrough Therapy Designation for povetacicept in IgA nephropathy with potential U.S. accelerated approval in H1 2026, completion of enrollment for the interim cohort of the Phase 2/3 AMPLITUDE trial of inaxaplin in APOL1-mediated kidney disease (also targeting accelerated approval), and initiation of a Phase 2 proof-of-concept study for VX-407 in autosomal dominant polycystic kidney disease, underscoring its push to deliver first-in-class therapies for serious kidney conditions.